ArticleACS materials Au2025
Nucleus-Targeted Delivery of Anticancer Drug Using Alpha-Synuclein(Y136C)-Gold Nanoparticle Conjugates.
Article in ACS materials Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nucleus plays a central role in eukaryotic cell survival by regulating essential processes. This makes it a strategic target for disrupting tumor growth in cancer therapy. Conventional nucleus-directed anticancer agents, including doxorubicin (Dox), have demonstrated effectiveness in treatment but face challenges related to poor cellular uptake and nuclear localization. To overcome these limitations, nanoparticle-based systems have been explored. In this study, α-synuclein-gold nanoparticle conjugates (αS-AuNPs) were employed as an intracellular drug delivery system for nuclear-targeted cancer therapy. αS, an intrinsically disordered protein, facilitates cellular uptake and nuclear accumulation. Dox was linked to αS-(Y136C)-AuNP via a heat-labile cross-linker, enabling controlled drug release upon near-infrared (NIR) irradiation. The photothermal effect of AuNPs induced localized hyperthermia, cleaving the linker. This facilitated the release of Dox directly into the nucleus, thereby enhancing its anticancer efficacy. This study demonstrates that Dox-αS-AuNP represents a promising nucleus-targeted drug delivery system for controlled and efficient cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.